Investment Thesis
GeoVax Labs is a pre-revenue pharmaceutical company in severe financial distress with zero revenue generation, operating losses of $5.3M, and negative free cash flow of -$3.5M. With only $1.3M in cash and a burn rate exceeding available reserves, the company faces critical liquidity challenges and viability concerns without immediate capital infusion or breakthrough revenue generation.
Strengths
- Minimal debt burden with Debt/Equity ratio of 0.00x
- $1.3M in cash provides near-term operational runway
- No significant capital expenditure requirements
Risks
- Zero revenue with no commercial products generating sales
- Operating cash burn of $3.5M annually against $1.3M cash reserve (~4-5 months runway)
- Current ratio of 1.06x indicates critically tight liquidity with minimal safety margin
- Negative ROE of -1065.7% and ROA of -176.4% reflect operational losses relative to minimal equity base
- Stockholders' equity of only $493.8K makes company highly vulnerable to dilutive financing
- Likely requires significant capital raise or revenue generation within months for survival
Key Metrics to Watch
- Cash balance trend and runway until additional capital needed
- Path to revenue generation and clinical trial/regulatory milestones
- Operating cash burn rate and burn trend
- Equity dilution from future financing events
- Clinical trial progression and product pipeline advancement
Financial Metrics
Revenue
0.0
Net Income
-5.3M
EPS (Diluted)
$0.00
Free Cash Flow
-3.5M
Total Assets
3.0M
Cash
1.3M
Profitability Ratios
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
ROE
-1,065.7%
ROA
-176.4%
FCF Margin
N/A
Balance Sheet & Liquidity
Current Ratio
1.06x
Quick Ratio
1.06x
Debt/Equity
0.00x
Debt/Assets
83.4%
Interest Coverage
N/A
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-15T07:21:53.453556 |
Data as of: 2026-03-31 |
Powered by Claude AI